CEO and team have delivered on 18 straight commitments early or on time since I first invested in this stock last yr.
The board and executive additions are unlike anything I have ever seen in the 35 yrs of investing in small caps. Nothing comes close.
Company is on track for revenue this yr and full out commercialization next.
This brilliant NeuroClear outta nowhere financing is clearly only the beginning of the formal launch of something special with respect to the neurology early stage assets that BSGM and the Mayo Clinic are working on.
This is a unique opportunity imo that wont last. This stock will be much higher by yr end and imo that is only the beginning.
Short interest is up substantially - they really imo don't understand the team they are betting against including Sam Navarro, Ken Londoner, John Kowalski and Dr Samuel J. Asirvatham, Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. Kowalski basically invented the pricing model and cardiac medical device industry new paradigm as we know it today. Sam Navarro has done 30 medical device deals and will be on the road with CEO in Sept. Mayo Clinic is fully committed and excited about the early stage pipeline and working with BSGM. Ken Londoner is a wall street veteran - a former short seller himself. The shorts will learn there are MUCH easier victims (who don't have a world class board or mgt team and dont make deadlines) out there by yr end IMO